Commercialisation of Animal Health products commences in international markets with Virbac


  • Creso confirms the first Purchase Order from Virbac global headquarters for its Animal Health products
  • The A$350k order follows the successful launch of anibidiol® into the Swiss & Liechtenstein markets late in 2017
  • Virbac markets and promotes the Creso Animal Health products in Europe and Latin America starting Q2 2019
  • Further orders into additional countries are planned
Creso Pharma Limited (ASX:CPH, FRA:1X8, the “Company” or “Creso”) confirmed today the first Purchase Order for A$350,000 from Virbac HQ for its Animal Health products.
The order comes off the back of the exclusive commercialisation agreement signed last month to expand marketing, promotion and distribution of Creso’s Animal Health products into 15 countries in Europe and Latin America following the successful launch in Switzerland and Liechtenstein.
The initial purchase order is for the launch, promotion and distribution of the
products by Virbac in several European countries starting Q2 2019.
Said Creso Pharma Co-Founder and Chief Executive Officer Dr. Miri Halperin Wernli: “We have had a promising start with our animal health products in Switzerland and Liechtenstein with very encouraging feedback from veterinarians, clinics and pet owners and we are now entering the expansion phase into many countries in Europe and Latin America.”
Creso and Virbac’s global reach puts them in a unique position to capture market share across the $69 billion annual pet industry.
– Ends –
ABN: 89 609 406 911
Level 24 , 300 Bar angaroo Avenue | Barangaroo, NSW, 2000 | Australia
Alte Steinhauserstrasse 10 | 6330 Cham | Schweiz
/Public Release.